Full Product Name
VHL Antibody
Product Gene Name
anti-VHL antibody
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
OMIM
AF010238 Genomic DNA
3D Structure
ModBase 3D Structure for P40337
Specificity
VHL Antibody detects endogenous levels of VHL protein.
Purity/Purification
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific peptide.
Form/Format
Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Concentration
1 mg/ml (lot specific)
Target Modification
Unmodified/Total
Immunogen
The antiserum was produced against synthesized peptide derived from the N-terminal region of human VHL.
Preparation and Storage
Store at -20 degree C for 1 year.
Other Notes
Small volumes of anti-VHL antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Applications Tested/Suitable for anti-VHL antibody
Immunohistochemistry (IHC) Paraffin, ELISA (EIA)
Application Notes for anti-VHL antibody
IHC-P: 1:50-1:300
ELISA: 1:10000
NCBI/Uniprot data below describe general gene information for VHL. It may not necessarily be applicable to this product.
NCBI Accession #
NP_000542.1
[Other Products]
NCBI GenBank Nucleotide #
NM_000551.3
[Other Products]
UniProt Primary Accession #
P40337
[Other Products]
UniProt Secondary Accession #
Q13599; Q6PDA9; B2RE45[Other Products]
UniProt Related Accession #
P40337[Other Products]
NCBI Official Full Name
von Hippel-Lindau disease tumor suppressor isoform 1
NCBI Official Synonym Full Names
von Hippel-Lindau tumor suppressor
NCBI Official Symbol
VHL [Similar Products]
NCBI Official Synonym Symbols
RCA1; VHL1; pVHL; HRCA1
[Similar Products]
NCBI Protein Information
von Hippel-Lindau disease tumor suppressor
UniProt Protein Name
von Hippel-Lindau disease tumor suppressor
UniProt Synonym Protein Names
Protein G7; pVHL
Protein Family
Von Hippel-Lindau disease tumor suppressor
UniProt Gene Name
VHL [Similar Products]
NCBI Summary for VHL
Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq, Jul 2008]
UniProt Comments for VHL
Involved in the ubiquitination and subsequent proteasomal degradation via the von Hippel-Lindau ubiquitination complex. Seems to act as a target recruitment subunit in the E3 ubiquitin ligase complex and recruits hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions. Involved in transcriptional repression through interaction with HIF1A, HIF1AN and histone deacetylases. Ubiquitinates, in an oxygen-responsive manner, ADRB2.
Research Articles on VHL
1. Our work provides the first evidence that VHL mutations positively correlate with PD-L1 expression in ccRCC and may influence the response to ccRCC anti-PD-L1/PD-1 immunotherapy.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
